High-dose intravenous epoetin does not increase blood pressure in critically ill patients with acute kidney injury

Ralib, Azrina; Pickering, John W.; Major, Tamás; Palmer, Suetonia C.; Goodkin, David A.; Endre, Zoltán H.

doi:10.5414/cn107673

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most previous NEE formulas used 1/100 or 1/150 as the conversion ratio for dopamine [12,15,16,20,23]. Two randomized trials showed that approximately 80 and 140 times the dose of dopamine was required to reach the same MAP target when compared with norepinephrine, respectively [31,32].…”

Section: Proposed Updated Norepinephrine Equivalent Scorementioning

confidence: 99%

“…However, the major issue with NEE is that there is no standardized method for measuring the potency of vasopressors. As a result, there are several different calculation formulas for NEE [12,13,15,16,[20][21][22][23]. Inconsistent calculation methods for NEE will make it difficult to compare or interpret the results between clinical studies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An updated “norepinephrine equivalent” score in intensive care as a marker of shock severity

et al. 2023

View full text Add to dashboard Cite

Vasopressors and fluids are the cornerstones for the treatment of shock. The current international guidelines on shock recommend norepinephrine as the first-line vasopressor and vasopressin as the second-line vasopressor. In clinical practice, due to drug availability, local practice variations, special settings, and ongoing research, several alternative vasoconstrictors and adjuncts are used in the absence of precise equivalent doses. Norepinephrine equivalence (NEE) is frequently used in clinical trials to overcome this heterogeneity and describe vasopressor support in a standardized manner. NEE quantifies the total amount of vasopressors, considering the potency of each such agent, which typically includes catecholamines, derivatives, and vasopressin. Intensive care studies use NEE as an eligibility criterion and also an outcome measure. On the other hand, NEE has several pitfalls which clinicians should know, important the lack of conversion of novel vasopressors such as angiotensin II and also adjuncts such as methylene blue, including a lack of high-quality data to support the equation and validate its predictive performance in all types of critical care practice. This review describes the history of NEE and suggests an updated formula incorporating novel vasopressors and adjuncts.

show abstract

Section: Proposed Updated Norepinephrine Equivalent Scorementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

An updated “norepinephrine equivalent” score in intensive care as a marker of shock severity

et al. 2023

View full text Add to dashboard Cite

show abstract

Harms of off-label erythropoiesis-stimulating agents for critically ill people

Mesgarpour

Heidinger

Roth

et al. 2017

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Low quality of evidence suggests that off-label use of ESAs may reduce mortality in a critical care setting. There was a lack of high-quality evidence about the harm of ESAs in critically-ill people. The information for biosimilar ESAs is less conclusive. Most studies neither evaluated ESAs' harm as a primary outcome nor predefined adverse events. Any further studies of ESA should address the quality of evaluating, recording and reporting of adverse events.

show abstract

High-dose intravenous epoetin does not increase blood pressure in critically ill patients with acute kidney injury

Abstract: We concluded that intravenous high dose epoetin does not acutely increase blood pressure, suggesting no acute vasoconstrictor effect in this setting.

Cited by 2 publications

References 0 publications

An updated “norepinephrine equivalent” score in intensive care as a marker of shock severity

An updated “norepinephrine equivalent” score in intensive care as a marker of shock severity

Harms of off-label erythropoiesis-stimulating agents for critically ill people

Contact Info

Product

Resources

About